Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of ASN51 with Fluvoxamine, Itraconazole, and Paroxetine
NCT06232109Phase 1Completed
- Sponsor
- Asceneuron SA
- Start
- Feb 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ASN51 in Alzheimer's disease (AD) (4 arms), sponsored by Asceneuron SA. Primary endpoints: Maximum Plasma Concentration (Cmax) of ASN51, Time to Maximum Plasma Concentration (Tmax) of ASN51 and 3 more. Started Feb 2024; status: completed.
02
Drugs
ASN51
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06232109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232109.